Regeneron shoots again with odronextamab
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.